Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.55 |
| ▸ | LMNA | P02545 | 5/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | DRD4 | P21917 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | MITF | O75030 | 1/20 | 0.47 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.47 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3845514 | 0.99 | ALDH1A1 (0.60) | ALDH1A1SMN1; SMN2LMNAGAAKDM4E | |
| SCHEMBL5069510 | 0.82 | MAPT (0.59) | ALDH1A1SMN1; SMN2LMNAGAAHTT | |
| SCHEMBL5069521 | 0.81 | ALDH1A1 (0.54) | ALDH1A1SMN1; SMN2LMNAGAAKDM4E | |
| Hydrochloric Acid SCHEMBL3843785 | 0.80 | ALDH1A1 (0.53) | ALDH1A1GAAKDM4EHTTKMT2A | |
| SCHEMBL5014357 | 0.78 | GAA (0.44) | ALDH1A1GAAHTTKMT2AMAPT | |
| SCHEMBL8188406 | 0.77 | ALDH1A1 (0.86) | ALDH1A1SMN1; SMN2LMNAGAAKDM4E | |
| SCHEMBL5070437 | 0.77 | GAA (0.46) | ALDH1A1GAAHTTHPGDMAPT | |
| SCHEMBL9826740 | 0.77 | ALDH1A1 (0.55) | ALDH1A1SMN1; SMN2LMNAGAAKDM4E | |
| SCHEMBL27707083 | 0.75 | ALDH1A1 (0.46) | ALDH1A1SMN1; SMN2LMNAGAAKDM4E | |
| SCHEMBL8916629 | 0.75 | ALDH1A1 (0.72) | ALDH1A1SMN1; SMN2LMNAGAAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1128830-B1 | REVERSING ADVANCED GLYCOSYLATION CROSS-LINKS USING HETEROCYCLIC-SUBSTITUTED THIAZOLIUM SALTS | SYNVISTA THERAPEUTICS INC (US) | 2008-03-12 | — | — | EP | claimed |
| US-6790859-B2 | THERAPY OR REDUCING PROGRESSION OF HYPERTENSION OR DAMAGE TO A TISSUE CAUSED BY CONTACT WITH ELEVATED LEVELS OF REDUCING SUGARS IN AN ANIMAL, COMPRISING ADMINISTERING TO THE ANIMAL AN EFFECTIVE AMOUNT OF THIAZOLIUM COMPOUNDS | ALTEON INCORPORATED | 2004-09-14 | — | — | US | claimed |
| EP-1128830-A4 | REVERSING ADVANCED GLYCOSYLATION CROSS-LINKS USING HETEROCYCLIC-SUBSTITUTED THIAZOLIUM SALTS | ALTEON INC (US) | 2004-03-31 | — | — | EP | claimed |
| US-20030176417-A1 | Reversing advanced glycosylation cross-links using heterocyclic-substituted thiazolium compounds | SYNVISTA THERAPEUTICS, INC. | 2003-09-18 | — | — | US | claimed |
| JP-2002529414-A | — | — | 2002-09-10 | — | — | JP | claimed |
| US-6319934-B1 | TREATING STIFFENING OF BLOOD VASCULATURE, ATHEROSCLEROSIS, RETINOPATHY, CATARACTS, PERIPHERAL NEUROPATHY OR OSTEOARTHRITIS IN AN ANIMAL | ALTEON, INC. | 2001-11-20 | — | — | US | claimed |
| EP-1128830-A1 | REVERSING ADVANCED GLYCOSYLATION CROSS-LINKS USING HETEROCYCLIC-SUBSTITUTED THIAZOLIUM SALTS | Alteon, Inc. (US) | 2001-09-05 | — | — | EP | claimed |
| US-6121300-A | IN A TOPICAL COSMETIC AS SKIN ELASTICITY IMPROVER OR WRINKLE REDUCER; COMPOUNDS SUCH AS 3-(2-(3-PHENYL-5-ISOXAZOLYL)-2-OXOETHYL)-THIAZOLIUM; ADMINSISTERING TO TREAT CATARACTS, PROTEIN AGING AND DIABETES | SYNVISTA THERAPEUTICS, INC. | 2000-09-19 | — | — | US | claimed |
| WO-2000027395-A1 | REVERSING ADVANCED GLYCOSYLATION CROSS-LINKS USING HETEROCYCLIC-SUBSTITUTED THIAZOLIUM SALTS | ALTEON, INC. (US) | 2000-05-18 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030176417-A1 | Reversing advanced glycosylation cross-links using heterocyclic-substituted thiazolium compounds | AGER, OGA, PTMS | ALDH1A1 1814/4885SMN1; SMN2 1872/4885LMNA 1577/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.